Skip to main content
SpringerLink
Log in

ONTARGET: How much RAS inhibition is enough?

  • Clinical Trials Report
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kunz R, Friedrish C, Wolbers M, Mann JFE: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48.

    PubMed  Google Scholar 

  2. Barnett AH, Bain SC, Bouter P, et al.; Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952–1961.

    Article  PubMed  CAS  Google Scholar 

  3. Hollenberg NK, Parving H-H, Viberti G, et al.: Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007, 25:1921–1926.

    Article  PubMed  CAS  Google Scholar 

  4. Parving H-H, Persson F, Lewis JB, et al.; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. New Engl J Med 2008, 358:2433–2446.

    Article  PubMed  CAS  Google Scholar 

  5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.

    Article  Google Scholar 

  6. Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033.

  7. The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.

    Article  Google Scholar 

  8. Kaplan NM: Recent clinical trials: the good, the bad, and the misleading. Hypertension 2008, 52:608–609.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Alan B. Weder
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weder, A.B. ONTARGET: How much RAS inhibition is enough?. Current Science Inc 11, 7–9 (2009). https://doi.org/10.1007/s11906-009-0002-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-009-0002-0

Keywords

Search

Navigation